ANI Pharmaceuticals (ANIP) AI Stock Analysis

• Market Cap: $1.96B
• Dividend Yield: N/A
• Average Volume (3M): 327.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.38
• Revenue Growth: 38.68%
• EPS Growth: -160.14%
• Country: US
• Employees: 897
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.04
• Shares Outstanding: 21,688,772
• 10 Day Avg. Volume: 467,727
• 30 Day Avg. Volume: 327,053
• PEG Ratio: 0.28
• Price to Book (P/B): 2.49
• Price to Sales (P/S): 1.74
• P/FCF Ratio: 22.69
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $108.60
• Price Target Upside: 20.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: $96.00 ▲(6.16% Upside)

ANI Pharmaceuticals' overall stock score is driven by strong earnings call performance and robust revenue growth. However, profitability challenges and a negative P/E ratio weigh on the valuation. Technical indicators suggest mixed momentum, with short-term bearish signals but longer-term bullish trends. The company's financial health is improving, but further efforts are needed to enhance profitability and shareholder returns.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Cash Flow Improvement

Enhanced cash generation capabilities improve financial flexibility, enabling strategic investments and debt reduction.

Rare Disease Business Expansion

Strong growth in the Rare Disease segment, particularly Cortrophin Gel, positions ANI for sustained market leadership and revenue diversification.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder reinvestment and shareholder returns, requiring strategic focus on cost management and margin improvement.

Generics Margin Pressure

Margin pressure in the Generics segment could impact overall profitability, necessitating efficiency improvements and cost control measures.

Return on Equity Concerns

Negative ROE indicates challenges in generating shareholder value, highlighting the need for strategic initiatives to enhance profitability.

ANI Pharmaceuticals Business Overview & Revenue Model

Company Description

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company primarily operates in the areas of niche and complex pharmaceuticals, with a portfolio that includes a wide range of products such as oral solid dosage forms, injectables, and complex formulations. ANI Pharmaceuticals is dedicated to addressing unmet medical needs and enhancing patient care through innovative drug delivery and therapeutic solutions.

How the Company Makes Money

ANI Pharmaceuticals generates revenue primarily through the sale of its branded and generic pharmaceutical products. The company has a diversified revenue model that includes direct sales to wholesalers, distributors, and retail pharmacies. Key revenue streams arise from the commercialization of its product portfolio, which consists of both established medications and newly developed products. Additionally, ANI Pharmaceuticals may engage in partnerships and collaborations with other pharmaceutical companies to co-develop or market products, further contributing to its earnings. The company also benefits from cost efficiencies in its manufacturing processes and regulatory approvals that enable it to bring products to market effectively.

ANI Pharmaceuticals Financial Statement Overview

Summary

ANI Pharmaceuticals shows strong revenue growth and improved cash flow generation, which are positive indicators for future performance. However, challenges with profitability and return on equity need to be addressed to enhance overall financial health. The balance sheet shows improved leverage management, but further efforts are required to improve shareholder returns.

Income Statement

ANI Pharmaceuticals has shown a positive revenue growth rate of 10.88% in the TTM, indicating strong sales momentum. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -1.48% and a low EBIT margin of 1.33%. The gross profit margin remains healthy at 57.95%, suggesting effective cost management at the production level. Overall, while revenue growth is promising, the company needs to address its profitability challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.73 in the TTM, which is an improvement from previous periods, indicating better leverage management. However, the return on equity is negative at -2.54%, reflecting challenges in generating returns for shareholders. The equity ratio is not provided, but the overall leverage position suggests a need for improved profitability to enhance shareholder value.

Cash Flow

The cash flow statement highlights a significant improvement in free cash flow growth at 129.53% in the TTM, demonstrating enhanced cash generation capabilities. The operating cash flow to net income ratio is 0.59, indicating a reasonable conversion of earnings to cash. The free cash flow to net income ratio is strong at 0.80, suggesting efficient cash management. Overall, the cash flow position is robust, supporting the company's operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	826.88M	614.38M	486.82M	316.38M	216.14M	208.47M
Gross Profit	371.13M	364.17M	305.30M	177.60M	115.53M	121.32M
EBITDA	159.57M	79.15M	106.60M	33.92M	-1.68M	24.23M
Net Income	40.57M	-18.52M	18.78M	-47.90M	-42.60M	-22.55M
Balance Sheet
Total Assets	1.41B	1.28B	904.42M	760.09M	771.60M	461.19M
Cash, Cash Equivalents and Short-Term Investments	262.61M	151.17M	221.12M	48.23M	100.30M	7.86M
Total Debt	322.63M	624.09M	285.67M	286.52M	287.37M	185.69M
Total Liabilities	902.34M	855.17M	446.82M	421.55M	412.86M	265.49M
Stockholders Equity	505.82M	428.53M	457.60M	338.54M	358.74M	195.70M
Cash Flow
Free Cash Flow	168.24M	47.06M	100.45M	-47.66M	-20.32M	-53.05M
Operating Cash Flow	170.72M	64.02M	118.96M	-31.20M	3.32M	15.27M
Investing Cash Flow	-43.60M	-404.72M	-18.51M	-15.74M	-105.48M	-68.32M
Financing Cash Flow	-10.21M	264.94M	67.44M	-5.13M	194.59M	-1.44M

ANI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 90.43
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIP, the sentiment is Negative. The current price of 90.43 is below the 20-day moving average (MA) of 92.52, below the 50-day MA of 93.58, and above the 200-day MA of 73.15, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 43.94 is Neutral, neither overbought nor oversold. The STOCH value of 43.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANIP.

ANI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	67 Neutral	$1.13B	9.00	18.32%	―	1.37%	-18.10%
ANIP	62 Neutral	$1.96B	―	-2.82%	―	38.68%	-160.14%
AVDL	61 Neutral	$1.85B	―	-0.32%	―	79.88%	99.60%
SUPN	55 Neutral	$2.64B	―	-1.86%	―	4.54%	-130.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCRX	46 Neutral	$981.78M	―	-15.57%	―	2.25%	-301.59%
HROW	36 Underperform	$1.31B	―	-18.99%	―	47.69%	69.57%

ANI Pharmaceuticals Corporate Events

ANI Pharmaceuticals Reports Record Q3 2025 Results

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company that develops, manufactures, and commercializes innovative therapeutics, focusing on rare diseases, generics, and branded products. The company is committed to improving lives through high-quality therapeutics across various medical fields.

ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares

On November 19, 2021, ANI Pharmaceuticals completed the acquisition of Novitium Pharma LLC and issued 25,000 shares of Series A Convertible Preferred Stock to Ampersand 2020 Limited Partnership for $25 million. By August 14, 2025, Ampersand converted 5,000 Preferred Shares into 120,580 Common Shares, and on September 26, 2025, the remaining 20,000 Preferred Shares were mandatorily converted into 482,320 Common Shares, resulting in no Preferred Shares remaining outstanding.

The most recent analyst rating on (ANIP) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Highlights Commercialization Focus Amid Challenges

ANI Pharmaceuticals‘ recent investor presentation highlights the company’s focus on the commercialization of its approved products and the challenges it faces due to acquisitions and supply chain issues. The presentation also discusses the company’s use of adjusted non-GAAP financial measures to provide a clearer picture of its operating performance, although it does not provide a reconciliation for the full-year 2025 adjusted EBITDA guidance due to insufficient information.

The most recent analyst rating on (ANIP) stock is a Hold with a $97.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals’ Record Earnings and Optimistic Outlook

ANI Pharmaceuticals Shines in Record-Setting Earnings Call

ANI Pharmaceuticals Reports Record Growth in Q2 2025

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing therapeutics across various medical fields, including rare diseases and generics.